文献速递心力衰竭与心肌病血脂与心血管预防

儿童癌症幸存者心脏疾病的转录组生物标志物:病例对照研究

Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study.
PubMed 文献 · Eur Heart J · 2026-01-01

该匹配病例对照研究纳入330例儿童癌症幸存者(165例心脏疾病患者与165例无心脏疾病对照),检测8557个基因表达,采用三种Lasso稳定化方法筛选与心脏疾病及心力衰竭相关的基因。

要点

  • NFE2L2表达降低与儿童癌症幸存者心脏疾病及心力衰竭风险相关。
  • 将NFE2L2表达纳入预后模型可改善对心脏疾病和心力衰竭的判别能力。
  • 未发现治疗剂量与NFE2L2表达水平之间的交互作用。

核心结论

  • NFE2L2基因表达降低与儿童癌症幸存者发生心脏疾病及心力衰竭相关。
  • 将NFE2L2表达纳入预后模型可提高对心脏疾病和心力衰竭的判别能力。

研究设计与样本

  • 匹配病例对照研究,样本为330例儿童癌症幸存者,其中165例心脏疾病病例和165例无心脏疾病对照。
  • 检测8557个基因表达,采用三种Lasso稳定化方法(Percentile lasso、Bolasso、Sublasso)筛选与心脏疾病及心力衰竭相关的基因。
  • 最终选择为三种方法所选基因集的交集,并探究癌症治疗剂量与所选基因的交互作用。

主要发现

  • 未发现治疗剂量与NFE2L2表达水平之间的交互作用。

临床怎么用

  • NFE2L2表达可作为儿童癌症幸存者心脏疾病和心力衰竭风险的潜在生物标志物。
  • 将NFE2L2表达纳入预后模型可能有助于改善风险分层。

局限性

  • 需要进一步研究验证该发现,并深入理解导致心脏毒性的生物学机制。
  • 研究未发现治疗剂量与NFE2L2表达水平的交互作用,需进一步探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Cardiotoxic treatments like anthracyclines and heart-directed radiotherapy increase the risk of cardiac diseases (CDs) in childhood cancer survivors (CCSs), but individual differences in CD incidence are not fully understood. This study aims to identify transcriptomic biomarkers associated with CD occurrence after childhood cancer treatment. METHODS: A matched case-control study was conducted on a sample of 330 CCS: 165 cases with CD and 165 CD-free controls. The expression of 8557 genes was investigated to select those associated with CD and heart failure (HF), using three stabilization approaches derived for the conditional logistic regression with Lasso (Percentile lasso, Bolasso, and Sublasso). The intersection of the three selected gene sets formed the final selection. The interactions between cancer treatment doses and selected genes were investigated. RESULTS: One promising gene, NFE2L2, constituted the final selection, and its expression was lower in cases than in controls [CD: odds ratio (OR) .16, 95% confidence interval (CI) .09-.29; HF: OR .11, 95% CI .03-.37]. No interaction between treatment doses and NFE2L2 expression levels was found in our study. Incorporating NFE2L2 gene expression into prognostic models improved discrimination between cases and controls compared with models based solely on clinical and treatment variables [CD: area under the curve (AUC) .85 vs .66; HF: AUC .87 vs .77]. CONCLUSIONS: Using high-dimensional data selection methods has enabled the identification of the gene NFE2L2, associated with CD and HF in CCS. Further research is needed to validate this finding and achieve a better understanding of the biological mechanisms leading to cardiac toxicities and so to develop risk-adapted treatment and surveillance strategies.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Aba N, Le Teuff G, Fresneau B, et al. Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study. Eur Heart J. 2026. PMID: 40985963. doi:10.1093/eurheartj/ehaf617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。